脂肪量和肥胖相關(guān)基因在代謝相關(guān)脂肪性肝病發(fā)生發(fā)展中的作用機(jī)制及相關(guān)靶向治療

打開文本圖片集

Abstract：Metabolicdysfunction-associatedfattyliverdisease（MAFLD）isacommonchronicliverdiseasewiththepathological featureoflipidaccumulationintheliver，nditisloselyasociatedwithlivermetabolicdisorders.Thelatestresearchhasshown thatthepathogenesisofMAFisassociatedwiththeabnoalexpresioofspecificgenes，especiallythefatmassandbsity associated（FTO）gene.Theabnormalactivityof theFTOgene mayleadtoanimbalanceinliverlipidmetabolism，whichmanifests astheincreaseinfattyacidsynthesisandthereductioninfatyacidoxidation，therebypromoting liverfatdepositionand inflammatoryresponse.ThereforeegulatingtheexpressionoractivityoftheFTOgeneisconsideredoneoftepotentialtategies forth treatmentofMAFLD.Atpresent，drugresearch targetingthfunctionoftheFOgenehasachievedpreliminaryresults，and inhibitionof theactivityoftheFTOgenecanhelptoregulateliverlipidmetabolismandallviateliverinflammatoryinjury.This articlereviewsthemechanismofactionof theFTOgeneinthedevelopmentandprogresionofMAFLD，summarizestheadvances in drugresearchontheFTO geneandrelated metabolic pathways inrecent years，andanalyzes theirapplication prospect in research and treatment.

Key Words：Alpha-Ketoglutarate-Dependent DioxygenaseFTO；Non-alcoholicFattLiver Disease；Lipid MetabolismDisorders； Genetic Therapy

Researchfunding：NationalNaturalScienceFoundationofChina（82160837）；GuangxiUniversityof Traditional Chinese MedicineQihuang EngineeringHigh-level TalentCultivation Project（2O21007）

代謝相關(guān)（非酒精性）脂肪性肝病（metabolicdysfunction-associatedfattyliverdisease，MAFLD）是一種廣泛性肝臟疾病，其主要特征是肝內(nèi)脂肪的異常積累，并可能進(jìn)一步導(dǎo)致肝纖維化、肝硬化、肝細(xì)胞癌，以及增加多種代謝并發(fā)癥的風(fēng)險(xiǎn)[1-2]。（剩余20148字）